Adalimumab or Infliximab for the Prevention of Early Postoperative Recurrence of Crohn Disease: Results From the ENEIDA Registry.
暂无分享,去创建一个
J. Gisbert | A. Montserrat | E. Cabré | J. Barrio | C. Taxonera | F. Gomollón | F. Bermejo | J. Pérez-Calle | E. Ricart | P. Nos | L. Fernández-Salazar | E. Doménech | M. Casanova | E. Garcia-Planella | M. Mañosa | P. Almela | R. Vicente | L. Rodríguez-Alonso | R. de Francisco | E. Iglesias-Flores | L. Ramos | R. Ríos León | L. de Castro | M. Rivero | M. Vera | F. Cañete | E. Hinojosa | A. Núñez-Alonso | P. Navarro | M. Navarro-Llavat | O. Benítez | P. Ramírez-de la Piscina | L. Márquez-Mosquera | R. C. González-Sueyro
[1] E. El Rassy,et al. Comparative Efficacy of Anti-TNF Therapies For The Prevention of Postoperative Recurrence of Crohn’s Disease , 2019, Journal of clinical gastroenterology.
[2] J. Gisbert,et al. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la utilidad de la determinación de calprotectina fecal en la enfermedad inflamatoria intestinal , 2018, Gastroenterología y Hepatología.
[3] X. Jouven,et al. Male gender, active smoking and previous intestinal resection are risk factors for post‐operative endoscopic recurrence in Crohn's disease: results from a prospective cohort study , 2018, Alimentary pharmacology & therapeutics.
[4] D. Sorrentino,et al. Clinically Significant Small Bowel Crohn's Disease Might Only be Detected by Capsule Endoscopy. , 2018, Inflammatory bowel diseases.
[5] S. Vermeire,et al. The operative risk and natural history after the diagnosis of ileal penetrating Crohn’s disease , 2018, European journal of gastroenterology & hepatology.
[6] J. Llach,et al. Comparison of Capsule Endoscopy and Magnetic Resonance Enterography for the Assessment of Small Bowel Lesions in Crohn's Disease. , 2018, Inflammatory bowel diseases.
[7] M. Kanda,et al. Postoperative adalimumab maintenance therapy for Japanese patients with Crohn’s disease: a single-center, single-arm phase II trial (CCOG-1107 study) , 2018, Surgery Today.
[8] Mamoru Watanabe,et al. Postoperative therapy with infliximab for Crohn’s disease: a 2-year prospective randomized multicenter study in Japan , 2018, Surgery Today.
[9] Jun Kato,et al. Efficacy of restarting anti-tumor necrosis factor α agents after surgery in patients with Crohn's disease , 2018, Intestinal research.
[10] J. Gisbert,et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the utility of the determination of faecal calprotectin in inflammatory bowel disease , 2018, Gastroenterología y Hepatología (English Edition).
[11] U. Kopylov,et al. The Association Between Drug Levels and Endoscopic Recurrence in Postoperative Patients with Crohn's Disease Treated with Tumor Necrosis Factor Inhibitors , 2017, Inflammatory bowel diseases.
[12] J. Gisbert,et al. Adalimumab vs Azathioprine in the Prevention of Postoperative Crohn’s Disease Recurrence. A GETECCU Randomised Trial , 2017, Journal of Crohn's & colitis.
[13] M. Mínguez,et al. Incidence and Management of Recurrence in Patients with Crohn's Disease Who Have Undergone Intestinal Resection: The Practicrohn Study , 2017, Inflammatory bowel diseases.
[14] S. Bonovas,et al. Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting , 2017, Digestion.
[15] J. Gisbert,et al. Recomendaciones del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU) sobre la monitorización, prevención y tratamiento de la recurrencia posquirúrgica en la enfermedad de Crohn , 2017 .
[16] J. Gisbert,et al. Recommendations of the Spanish Working Group on Crohn's Disease and Ulcerative Colitis (GETECCU) on the monitoring, prevention and treatment of post-operative recurrence in Crohn's disease. , 2017 .
[17] C. Buskens,et al. 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 2: Surgical Management and Special Situations. , 2017, Journal of Crohn's & colitis.
[18] L. Peyrin-Biroulet,et al. Previous Exposure to Multiple Anti-TNF Is Associated with Decreased Efficiency in Preventing Postoperative Crohn’s Disease Recurrence , 2016, Journal of Crohn's & colitis.
[19] Siddharth Singh,et al. American Gastroenterological Association Institute Guideline on the Management of Crohn's Disease After Surgical Resection. , 2017, Gastroenterology.
[20] A. Ford,et al. Postoperative prophylaxis in Crohn's disease after intestinal resection: a retrospective analysis , 2016, Frontline Gastroenterology.
[21] H. Isomoto,et al. Clinical efficacy of adalimumab in Crohn’s disease: a real practice observational study in Japan , 2016, BMC Gastroenterology.
[22] M. Regueiro,et al. Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn's Disease After Ileocolonic Resection. , 2016, Gastroenterology.
[23] B. Nørgård,et al. Postoperative Use of Anti-TNF-&agr; Agents in Patients with Crohn's Disease and Risk of Reoperation—A Nationwide Cohort Study , 2016, Inflammatory bowel diseases.
[24] M. Kamm,et al. Efficacy of thiopurines and adalimumab in preventing Crohn's disease recurrence in high‐risk patients – a POCER study analysis , 2015, Alimentary pharmacology & therapeutics.
[25] Steven J Brown,et al. Crohn's disease management after intestinal resection: a randomised trial , 2015, The Lancet.
[26] E. Cabré,et al. Optimizing post-operative Crohn’s disease treatment , 2014, Annals of gastroenterology.
[27] A. Tursi,et al. Comparison of the effectiveness of infliximab and adalimumab in preventing postoperative recurrence in patients with Crohn’s disease: an open-label, pilot study , 2014, Techniques in Coloproctology.
[28] E. Cabré,et al. An Overview of the Natural History of Inflammatory Bowel Diseases , 2014, Digestive Diseases.
[29] Koji Tanaka,et al. The impact of postoperative infliximab maintenance therapy on preventing the surgical recurrence of Crohn’s disease: a single-center paired case–control study , 2014, Surgery Today.
[30] L. Guidi,et al. Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study. , 2013, Journal of Crohn's & colitis.
[31] E. Savarino,et al. Adalimumab Is More Effective Than Azathioprine and Mesalamine at Preventing Postoperative Recurrence of Crohn's Disease: A Randomized Controlled Trial , 2013, The American Journal of Gastroenterology.
[32] E. Cabré,et al. Addition of Metronidazole to Azathioprine for the Prevention of Postoperative Recurrence of Crohn’s Disease: A Randomized, Double-Blind, Placebo-Controlled Trial , 2013, Inflammatory bowel diseases.
[33] G. Mantzaris,et al. Adalimumab for the prevention and/or treatment of post-operative recurrence of Crohn's disease: a prospective, two-year, single center, pilot study. , 2012, Journal of Crohn's & colitis.
[34] H. Ikeuchi,et al. Scheduled infliximab monotherapy to prevent recurrence of Crohn's disease following ileocolic or ileal resection: A 3‐year prospective randomized open trial , 2012, Inflammatory bowel diseases.
[35] C. Sánchez-Montes,et al. Adalimumab in prevention of postoperative recurrence of Crohn's disease in high-risk patients. , 2012, World journal of gastroenterology.
[36] E. Savarino,et al. Adalimumab for the prevention of recurrence after surgery for Crohn’s disease: author’s reply , 2012 .
[37] H. Ogata,et al. The use of infliximab in the prevention of postsurgical recurrence in polysurgery Crohn's disease patients: a pilot open-labeled prospective study , 2012, International Journal of Colorectal Disease.
[38] M. Geraci,et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. , 2010, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[39] P. Rutgeerts,et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. , 2010, The New England journal of medicine.
[40] Laurent Beaugerie,et al. The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Definitions and diagnosis. , 2006, Journal of Crohn's & colitis.
[41] M. Regueiro,et al. Infliximab prevents Crohn's disease recurrence after ileal resection. , 2009, Gastroenterology.
[42] C. Avellini,et al. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. , 2007, Archives of internal medicine.
[43] P. Rutgeerts,et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. , 1998, Gastroenterology.
[44] P. Rutgeerts,et al. Predictability of the postoperative course of Crohn's disease. , 1990, Gastroenterology.